The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety Information (Adverse Event)
Timeframe: 24 weeks from the initiation of brexpiprazole treatment
Safety Information (Special Situations)
Timeframe: 24 weeks from the initiation of brexpiprazole treatment
Safety Information (Number of off-Label Use)
Timeframe: 24 weeks from the initiation of brexpiprazole treatment
Safety Information (Serious Adverse Event)
Timeframe: 24 weeks from the initiation of brexpiprazole treatment
Safety Information (Non-serious Adverse Events)
Timeframe: 24 weeks from the initiation of brexpiprazole treatment
Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd